Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. 2010

Daniel Weintraub, and Mandy Sohr, and Marc N Potenza, and Andrew D Siderowf, and Mark Stacy, and Valerie Voon, and Jacqueline Whetteckey, and Glen R Wunderlich, and Anthony E Lang
Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA, USA. daniel.weintraub@uphs.upenn.edu

A recent controlled clinical trial suggested a role for amantadine as a treatment for pathological gambling in patients with Parkinson disease (PD). Analyzing data from a large cross-sectional study of impulse control disorders (ICDs) in PD, amantadine use (n = 728), vs no amantadine use (n = 2,357), was positively associated with a diagnosis of any ICD (17.6% vs 12.4%, p < 0.001) and compulsive gambling specifically (7.4% vs 4.2%, p < 0.001). This amantadine association remained after controlling for covariates of amantadine use, including both dopamine agonist use and levodopa dosage. Further research, including larger clinical trials, is needed to assess the role of amantadine in the development and treatment of ICDs in PD.

UI MeSH Term Description Entries
D007174 Disruptive, Impulse Control, and Conduct Disorders Disorders whose essential features are the failure to resist an impulse, drive, or temptation to perform an act that is harmful to the individual or to others. Individuals experience an increased sense of tension prior to the act and pleasure, gratification or release of tension at the time of committing the act. Impulse Control Disorders,Intermittent Explosive Disorder,Kleptomania,Impulse-Control Disorders,Disorders, Impulse Control,Disorders, Intermittent Explosive,Explosive Disorder, Intermittent,Intermittent Explosive Disorders
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D003430 Cross-Sectional Studies Studies in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at one particular time. This contrasts with LONGITUDINAL STUDIES which are followed over a period of time. Disease Frequency Surveys,Prevalence Studies,Analysis, Cross-Sectional,Cross Sectional Analysis,Cross-Sectional Survey,Surveys, Disease Frequency,Analyses, Cross Sectional,Analyses, Cross-Sectional,Analysis, Cross Sectional,Cross Sectional Analyses,Cross Sectional Studies,Cross Sectional Survey,Cross-Sectional Analyses,Cross-Sectional Analysis,Cross-Sectional Study,Cross-Sectional Surveys,Disease Frequency Survey,Prevalence Study,Studies, Cross-Sectional,Studies, Prevalence,Study, Cross-Sectional,Study, Prevalence,Survey, Cross-Sectional,Survey, Disease Frequency,Surveys, Cross-Sectional
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000547 Amantadine An antiviral that is used in the prophylactic or symptomatic treatment of influenza A. It is also used as an antiparkinsonian agent, to treat extrapyramidal reactions, and for postherpetic neuralgia. The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake. 1-Aminoadamantane,Adamantylamine,Adekin,Aman,Amanta,Amanta-HCI-AZU,Amanta-Sulfate-AZU,Amantadin AL,Amantadin AZU,Amantadin Stada,Amantadin-neuraxpharm,Amantadin-ratiopharm,Amantadina Juventus,Amantadina Llorente,Amantadine Hydrochloride,Amantadine Sulfate,Amixx,Cerebramed,Endantadine,Gen-Amantadine,Infecto-Flu,Infex,Mantadix,Midantan,PMS-Amantadine,Symadine,Symmetrel,Viregyt,Wiregyt,tregor,1 Aminoadamantane,AL, Amantadin,AZU, Amantadin,Amanta HCI AZU,Amanta Sulfate AZU,AmantaHCIAZU,AmantaSulfateAZU,Amantadin neuraxpharm,Amantadin ratiopharm,Amantadinneuraxpharm,Amantadinratiopharm,Gen Amantadine,GenAmantadine,Hydrochloride, Amantadine,Infecto Flu,InfectoFlu,Juventus, Amantadina,Llorente, Amantadina,PMS Amantadine,PMSAmantadine,Stada, Amantadin,Sulfate, Amantadine
D000978 Antiparkinson Agents Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists. Antiparkinson Drugs,Antiparkinsonian Agents,Antiparkinsonians,Agents, Antiparkinson,Agents, Antiparkinsonian,Drugs, Antiparkinson

Related Publications

Daniel Weintraub, and Mandy Sohr, and Marc N Potenza, and Andrew D Siderowf, and Mark Stacy, and Valerie Voon, and Jacqueline Whetteckey, and Glen R Wunderlich, and Anthony E Lang
February 2011, Nature reviews. Neurology,
Daniel Weintraub, and Mandy Sohr, and Marc N Potenza, and Andrew D Siderowf, and Mark Stacy, and Valerie Voon, and Jacqueline Whetteckey, and Glen R Wunderlich, and Anthony E Lang
April 2019, Revue neurologique,
Daniel Weintraub, and Mandy Sohr, and Marc N Potenza, and Andrew D Siderowf, and Mark Stacy, and Valerie Voon, and Jacqueline Whetteckey, and Glen R Wunderlich, and Anthony E Lang
May 2010, Archives of neurology,
Daniel Weintraub, and Mandy Sohr, and Marc N Potenza, and Andrew D Siderowf, and Mark Stacy, and Valerie Voon, and Jacqueline Whetteckey, and Glen R Wunderlich, and Anthony E Lang
October 2006, Neurology,
Daniel Weintraub, and Mandy Sohr, and Marc N Potenza, and Andrew D Siderowf, and Mark Stacy, and Valerie Voon, and Jacqueline Whetteckey, and Glen R Wunderlich, and Anthony E Lang
October 2013, Journal of clinical psychopharmacology,
Daniel Weintraub, and Mandy Sohr, and Marc N Potenza, and Andrew D Siderowf, and Mark Stacy, and Valerie Voon, and Jacqueline Whetteckey, and Glen R Wunderlich, and Anthony E Lang
August 2018, Sleep medicine,
Daniel Weintraub, and Mandy Sohr, and Marc N Potenza, and Andrew D Siderowf, and Mark Stacy, and Valerie Voon, and Jacqueline Whetteckey, and Glen R Wunderlich, and Anthony E Lang
July 2006, Archives of neurology,
Daniel Weintraub, and Mandy Sohr, and Marc N Potenza, and Andrew D Siderowf, and Mark Stacy, and Valerie Voon, and Jacqueline Whetteckey, and Glen R Wunderlich, and Anthony E Lang
December 2012, Neurology. Clinical practice,
Daniel Weintraub, and Mandy Sohr, and Marc N Potenza, and Andrew D Siderowf, and Mark Stacy, and Valerie Voon, and Jacqueline Whetteckey, and Glen R Wunderlich, and Anthony E Lang
December 2012, Journal of neurology,
Daniel Weintraub, and Mandy Sohr, and Marc N Potenza, and Andrew D Siderowf, and Mark Stacy, and Valerie Voon, and Jacqueline Whetteckey, and Glen R Wunderlich, and Anthony E Lang
February 2020, Clinics in geriatric medicine,
Copied contents to your clipboard!